类风湿关节炎药物随机对照试验缺失数据量大且处理不当
该研究分析类风湿关节炎药物随机对照试验中缺失数据的数量、报告与处理方法,以及意向性治疗(ITT)原则应用和敏感性分析使用情况,并比较2006年与2016年的报告趋势。共纳入176项试验,中位入组160例患者,发现近三分之一试验主要结局缺失数据超过20%,缺失数据处理报告与方法仍不充分,敏感性分析使用率低,十年间未见改善趋势。
要点
- 近三分之一类风湿关节炎药物随机对照试验主要结局缺失数据超过20%。
- 仅58/97(59.8%)报告ITT分析的试验实际执行了ITT。
- 缺失数据处理方法多为简单填补,敏感性分析使用率低且十年无改善。
核心结论
- 类风湿关节炎药物随机对照试验中报告的分析与实际执行的分析存在显著差异。
- 近三分之一试验主要结局缺失数据超过20%,缺失数据处理报告与方法仍不充分。
- 敏感性分析使用率低,2006年至2016年缺失数据报告与处理未见改善趋势。
研究设计与样本
- 平行组药物疗法类风湿关节炎随机对照试验,具有临床主要终点。
- 共纳入176项研究,中位入组160例患者(IQR 62-339)。
- 比较2006年与2016年相隔十年的报告趋势。
主要发现
- 81项(46%)试验执行ITT分析,42项(23.9%)执行改良ITT,53项(30.1%)执行非ITT分析。
- 97项报告ITT分析的试验中仅58项(59.8%)实际执行ITT。
- 完成试验和纳入主要结局分析的患者中位数分别为86%(IQR 74%-91%)和100%(IQR 97.1%-100%)。
- 53项(32.7%)试验主要结局缺失数据超过20%,65项(40.1%)缺失10%-20%。
- 171项试验中58项(33.9%)未报告缺失数据处理方法,报告者绝大多数使用简单填补方法。
关键数值与推荐
- 主要结局缺失数据超过20%的试验为53项(32.7%)。
- 主要结局缺失数据10%-20%的试验为65项(40.1%)。
- 未报告缺失数据处理方法的试验为58/171(33.9%)。
- 敏感性分析使用率2006年为14.7%,2016年为21.4%。
临床怎么用
- 解读类风湿关节炎药物随机对照试验时需关注实际执行的分析是否与报告一致。
- 主要结局缺失数据超过20%时需谨慎解释结果,并关注缺失数据处理方法是否合理。
- 应重视敏感性分析结果以评估结论稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To analyse the amount, reporting and handling of missing data, approach to intention-to-treat (ITT) principle application and sensitivity analysis utilisation in randomised clinical trials (RCTs) of rheumatoid arthritis (RA). To assess the trend in such reporting 10 years apart (2006 and 2016). METHODS: Parallel group drug therapy RA RCTs with a clinical primary endpoint. RESULTS: 176 studies enrolling a median of 160 (IQR 62-339) patients were eligible. In terms of actual analysis: 81 (46%) RCTs conducted ITT, 42 (23.9%) conducted modified ITT while 53 (30.1%) conducted non-ITT analysis. Only 58 of 97 (59.8%) RCTs reporting an ITT analysis actually performed it. The median (IQR) numbers of participants completing the trial and included in analysis for primary outcome were 86% (74%-91%) and 100% (97.1%-100%), respectively. 53 (32.7%) and 65 (40.1%) RCTs had >20% and 10%-20% missing primary outcome data, respectively. Missing data handling was unreported by 58 of 171 (33.9%) RCTs. When reported, vast majority used simple imputation methods. No significant trend towards improved reporting was seen between 2006 and 2016. Sensitivity analysis numerically improved from 2006 to 2016 (14.7% vs 21.4%). CONCLUSIONS: There is significant discrepancy in the reported and the actual performed analysis in RA drug therapy RCTs. Nearly one-third of RCTs had >20% missing data. The reporting and methods of missing data handling remain inadequate with high usage of non-preferred simple imputation methods. Sensitivity analysis utilisation was low. No trend towards better missing data reporting and handling was seen.
引用
- Khan NA, Torralba KD, Aslam F, et al. Missing data in randomised controlled trials of rheumatoid arthritis drug therapy are substantial and handled inappropriately. RMD Open. 2021. PMID: 34330848. doi:10.1136/rmdopen-2021-001708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。